{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017877", "CSN": null, "TRF": "ORD_1256018_01", "MRN": "36563436", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "983160", "clinicalId": "984544", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1256018_01", "SampleName": "US1216136.01", "Version": "0", "Sample": {"FM_Id": "ORD_1256018_01", "SampleId": "US1216136.01", "BlockId": "S110-62229A", "TRFNumber": "ORD_1256018_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_12_15", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98002", "MRN": "36563436", "FullName": "\u8449\u69ae\u8f1d", "FirstName": "Jung_Hui", "LastName": "Yeh", "SubmittedDiagnosis": "Adenocarcinoma, Liver", "Gender": "Male", "DOB": "1948_10_15", "OrderingMD": "\u4faf\u660e\u5fd7", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Liver", "CollDate": "2021_11_29", "ReceivedDate": "2022-01-04 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Adenocarcinoma, NOS"}, "PertinentNegatives": {"PertinentNegative": {"Gene": "FGFR2"}}, "Summaries": {"alterationCount": "15", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "BARD1", "isVUS": "true", "variantName": "I258V"}, {"geneName": "CDKN2A/B", "isVUS": "true", "variantName": "R73G"}, {"geneName": "DDR2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "HSD3B1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "G1312S"}, {"geneName": "MYCL1", "isVUS": "true", "variantName": "Y43C"}, {"geneName": "NOTCH2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NTRK1", "isVUS": "true", "variantName": "P397T,R220W"}, {"geneName": "POLE", "isVUS": "true", "variantName": "H1810L"}, {"geneName": "TEK", "isVUS": "true", "variantName": "Y1024F"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "IDH1", "Include": "true", "Alterations": {"Alteration": {"Name": "R132C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R132C"}}, "Interpretation": "The isocitrate dehydrogenases IDH1 and IDH2 encode highly homologous enzymes that are involved in the citric acid (TCA) cycle and other metabolic processes, playing roles in normal cellular metabolism and in protection against oxidative stress and apoptosis (Reitman and Yan, 2010; 20513808). R132 is located within the active site of IDH1 and is a hotspot for mutations in cancer (Jin et al., 2011; 21326614, Gross et al., 2010; 20142433, Ward et al., 2010; 20171147, Leonardi et al., 2012; 22442146, Reitman and Yan, 2010; 20513808). Substitutions at IDH1 R132 alter the enzymatic activity of IDH1, resulting in the production of the oncometabolite, D_2_hydroxyglutarate (2_HG)(Dang et al., 2009; 19935646, Ward et al., 2012; 21996744, Ward et al., 2010; 20171147, Gross et al., 2010; 20142433, Leonardi et al., 2012; 22442146), which promotes tumorigenesis (Gross et al., 2010; 20142433, Figueroa et al., 2010; 21130701, Xu et al., 2011; 21251613, Turcan et al., 2012; 22343889, Duncan et al., 2012; 22899282). IDH1 or IDH2 mutation has been reported in 10_23% of cholangiocarcinoma cases and has been found to be more prevalent in intrahepatic (22_28%) than extrahepatic (0_7%) cholangiocarcinomas (Voss et al., 2013; 23391413, Sia et al., 2013; 23318457, Kipp et al., 2012; 22503487, Ross et al., 2014; 24563076, Borger et al., 2012; 22180306, Wang et al., 2013; 22824796). In patients with intrahepatic cholangiocarcinoma, IDH1/2 mutations are associated with longer OS and increased time to tumor recurrence (Wang et al., 2013; 22824796). A preclinical study observed that mutant IDH can block hepatocyte differentiation and cooperate with oncogenic KRAS to drive cholangiocarcinoma development (Saha et al., 2014; 25043045). IDH1 mutations that lead to production of 2_HG, most commonly R132 alterations, may predict sensitivity to IDH1_mutation_specific inhibitors such as ivosidenib (Abou_Alfa et al., 2019; ESMO Abstract LBA10, Fan et al., 2019; 31028664, Mellinghoff et al., 2017; SNO Abstract ACTR_46, Tap et al., 2016; CTOS Abstract P1_138). A Phase 1b/2 study of the IDH1 inhibitor olutasidenib for patients with IDH1_mutated glioma reported a DCR of 50% (n=24) with 1 PR (De La Fuente et al., 2020; ASCO Abstract 2505). A Phase 1 study of the pan_IDH1/IDH2 inhibitor vorasidenib for patients with IDH1_ or IDH2_mutated glioma reported an ORR of 18.2% (4/22; RANO criteria) and median PFS of 31.4 months for non_enhancing cases and median PFS of 7.5 months for the overall glioma population (n=52) (Mellinghoff et al., 2020; ASCO Abstract 2504). Preclinical studies suggested that IDH1 neomorphic mutations may also confer sensitivity to PARP inhibitors (Philip et al., 2018; 29719265, Molenaar et al., 2018; 29339439, Lu et al., 2017; 28202508, Sulkowski et al., 2017; 28148839).", "Include": "true", "ClinicalTrialNote": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Ivosidenib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML) or previously treated locally advanced or metastatic cholangiocarcinoma. It is also approved as a first_line treatment for patients with AML and a susceptible IDH1 mutation who are not eligible for intensive induction chemotherapy or who are \u226575 years old. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical evidence in AML (DiNardo et al., 2018; 29860938) and cholangiocarcinoma (Lowery et al., 2019; 31300360, Abou_Alfa et al., 2020; 32416072) and limited clinical data in myelodysplastic syndrome (MDS) (DiNardo et al., 2018; 29860938) and glioma (Mellinghoff et al., 2020; 32530764, Fan et al., 2019; 31028664), IDH1 R132 mutation may confer sensitivity to ivosidenib. </p> <p><b>Supporting Data:</b> In the Phase 3 ClarIDHy trial for patients with previously treated IDH1 R132_mutated cholangiocarcinoma, ivosidenib significantly increased PFS (2.7 vs. 1.4 months, HR=0.37, p <0.001) as well as PFS rates compared with placebo (6_month: 32% vs. 0%, 12_month: 22% vs. 0%) and reported numerically increased OS (10.3 vs. 7.5 months, HR=0.79, p=0.09), which reached statistical significance once adjusted for crossover (10.3 vs. 5.1 months, HR=0.49, p <0.0001) (Abou_Alfa et al., 2020; 32416072, Zhu et al., 2021; 34554208). A Phase 1 study reported an ORR of 5.6% (4/72, all PRs), SD rate of 56% (40/72), median PFS of 3.8 months, and median OS of 13.8 months for patients with IDH1_mutated cholangiocarcinoma treated with ivosidenib (Lowery et al., 2019; 31300360). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04298021", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT03907969", "Include": "true"}, {"nctId": "NCT03878095", "Include": "true"}, {"nctId": "NCT03830918", "Include": "true"}, {"nctId": "NCT03212274", "Include": "true"}, {"nctId": "NCT03221400", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non_zero level of MSI has been reported in 18_49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI_H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). One study reported that MSI is associated with poor prognosis in liver fluke_related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PBRM1", "Include": "true", "Alterations": {"Alteration": {"Name": "S934fs*74", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S934fs*74"}}, "Interpretation": "PBRM1 (Polybromo_1), also known as BAF180, encodes a subunit of ATP_dependent chromatin_remodeling complexes and a required cofactor for ligand_dependent transactivation by nuclear hormone receptors (Lemon et al., 2001; 11780067). Mutation, loss, or inactivation of PBRM1 has been reported in several cancers, suggesting PBRM1 is a tumor suppressor (Varela et al., 2011; 21248752, Jiao et al., 2013; 24185509, Xia et al., 2008; 18339845). Alterations such as seen here may disrupt PBRM1 function or expression (Hopson and Thompson, 2017; 28921948, Porter et al., 2017; 28053089, Niimi et al., 2015; 26117423, Brownlee et al., 2014; 24613357, Kakarougkas et al., 2014; 25066234, Gao et al., 2017; 28082722). Somatic mutations in PBRM1 are prevalent in clear cell renal cell carcinomas (ccRCC) (41%) (Varela et al., 2011; 21248752), intrahepatic cholangiocarcinomas (9_13%) (Fujimoto et al., 2015; 25636086, Jiao et al., 2013; 24185509, Churi et al., 2014; 25536104, Simbolo et al., 2014; 24867389), and bladder urothelial carcinomas (6_14%) (cBio_Cancer Genome Atlas Research Network, 2014; 24476821, cBio_Robertson et al., 2017; 28988769, cBio_Pietzak et al., 2017; 28583311). PBRM1 mutations are detected in other tumor types, including in 37% (11/30) of papillary meningiomas and 4% (2/54) of thymic carcinomas (Williams et al., 2020; 32405805, Petrini et al., 2014; 24974848) and in skin (6%), large intestine (5%), stomach (5%), soft tissue (3%), and lung (2%) (COSMIC, 2021)(Tate et al., 2019; 30371878). Preclinical studies have shown that loss of PBRM1 increases the proliferation of ccRCC cell lines (Varela et al., 2011; 21248752). PBRM1 protein loss or mutation is correlated with late tumor stage, low differentiation grade, and/or poor patient prognosis in ccRCC (da Costa et al., 2014; 24053427, Paw\u0142owski et al., 2013; 22949125, Hakimi et al., 2013; 23036577), extrahepatic cholangiocarcinoma (Churi et al., 2014; 25536104), and pancreatic cancer (Numata et al., 2013; 23229642). However, one ccRCC study reported no correlation between PBRM1 mutation and cancer_specific survival (Hakimi et al., 2013; 23620406). In ccRCC, PBRM1 alterations are generally observed to be mutually exclusive with BAP1 alterations (Varela et al., 2011; 21248752, Pena_Llopis et al., 2012; 22683710); a retrospective analysis of 145 primary ccRCCs found a decreased median overall survival for patients with mutations in both BAP1 and PBRM1 compared with patients having either mutated gene alone (Kapur et al., 2013; 23333114). A trend toward worse survival was also seen in patients with intrahepatic cholangiocarcinoma harboring mutations in chromatin modifiers (including BAP1, ARID1A, or PBRM1) (Jiao et al., 2013; 24185509). On the basis of significant clinical data from prospective studies, PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma and prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). However, multiple retrospective analyses report that PBRM1 mutation status is not associated with clinical benefit from various immune checkpoint inhibitors in other solid tumor types, including non_small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of PBRM1 loss of function may depend on tumor type (Abou Alaiwi et al., 2020; 32321774, Hakimi et al., 2020; 32820162, Miao et al., 2018; 30150660, Yang et al., 2021; 33850862).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "03", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "03"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Cholangiocarcinoma harbors a median TMB of 2.5 mutations per megabase (muts/Mb), and 1.9% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study (Nakamura et al., 2015; 26258846), TMB_high (\u226510 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB_high tumors experienced numerically longer OS compared with patients with TMB_low tumors (11.5 vs. 8.4 months, adjusted HR=0.65) (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "IDH1", "Alteration": "R132C", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "DDR_Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer", "StudyPhase": "PHASE 2", "Target": "PD_L1, ATR, PARP", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT04298021", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti_cancer Agents in Patients With Advanced Cancers", "StudyPhase": "PHASE 1/2", "Target": "PARP, DNA_PK", "Locations": "Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas", "NCTID": "NCT03907969", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors", "StudyPhase": "PHASE 2", "Target": "ATR, PARP", "Locations": "Utah, Wisconsin, Michigan, Ohio, Connecticut, Maryland, Texas, Florida", "NCTID": "NCT03878095", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "Niraparib and Temozolomide in Treating Patients With Extensive_Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum_Based First_Line Chemotherapy", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "California", "NCTID": "NCT03830918", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "California, Wisconsin, Missouri, Kansas", "NCTID": "NCT03212274", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132C", "Title": "PEN_866 in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "PARP, HSP90", "Locations": "Nevada, Colorado, Michigan, Oklahoma, Arkansas, Tennessee, Pennsylvania, Maryland, Virginia", "NCTID": "NCT03221400", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "20513808", "FullCitation": "Reitman ZJ, et al. J. Natl. Cancer Inst. (2010) pmid: 20513808", "Include": "true"}, {"number": "1", "ReferenceId": "21326614", "FullCitation": "Jin G, et al. PLoS ONE (2011) pmid: 21326614", "Include": "true"}, {"number": "2", "ReferenceId": "20142433", "FullCitation": "Gross S, et al. J. Exp. Med. (2010) pmid: 20142433", "Include": "true"}, {"number": "3", "ReferenceId": "20171147", "FullCitation": "Ward PS, et al. Cancer Cell (2010) pmid: 20171147", "Include": "true"}, {"number": "4", "ReferenceId": "22442146", "FullCitation": "Leonardi R, et al. J. Biol. Chem. (2012) pmid: 22442146", "Include": "true"}, {"number": "5", "ReferenceId": "19935646", "FullCitation": "Dang L, et al. Nature (2009) pmid: 19935646", "Include": "true"}, {"number": "6", "ReferenceId": "21996744", "FullCitation": "Ward PS, et al. Oncogene (2012) pmid: 21996744", "Include": "true"}, {"number": "7", "ReferenceId": "21130701", "FullCitation": "Figueroa ME, et al. Cancer Cell (2010) pmid: 21130701", "Include": "true"}, {"number": "8", "ReferenceId": "21251613", "FullCitation": "Xu W, et al. Cancer Cell (2011) pmid: 21251613", "Include": "true"}, {"number": "9", "ReferenceId": "22343889", "FullCitation": "Turcan S, et al. Nature (2012) pmid: 22343889", "Include": "true"}, {"number": "10", "ReferenceId": "22899282", "FullCitation": "Duncan CG, et al. Genome Res. (2012) pmid: 22899282", "Include": "true"}, {"number": "11", "ReferenceId": "23391413", "FullCitation": "Voss JS, et al. Hum. Pathol. (2013) pmid: 23391413", "Include": "true"}, {"number": "12", "ReferenceId": "23318457", "FullCitation": "Sia D, et al. Oncogene (2013) pmid: 23318457", "Include": "true"}, {"number": "13", "ReferenceId": "22503487", "FullCitation": "Kipp BR, et al. Hum. Pathol. (2012) pmid: 22503487", "Include": "true"}, {"number": "14", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "15", "ReferenceId": "22180306", "FullCitation": "Borger DR, et al. Oncologist (2012) pmid: 22180306", "Include": "true"}, {"number": "16", "ReferenceId": "22824796", "FullCitation": "Wang P, et al. Oncogene (2013) pmid: 22824796", "Include": "true"}, {"number": "17", "ReferenceId": "25043045", "FullCitation": "Saha SK, et al. Nature (2014) pmid: 25043045", "Include": "true"}, {"number": "18", "ReferenceId": "31028664", "FullCitation": "Fan B, et al. Invest New Drugs (2019) pmid: 31028664", "Include": "true"}, {"number": "19", "ReferenceId": "29719265", "FullCitation": "Philip B, et al. Cell Rep (2018) pmid: 29719265", "Include": "true"}, {"number": "20", "ReferenceId": "29339439", "FullCitation": "Molenaar RJ, et al. Clin. Cancer Res. (2018) pmid: 29339439", "Include": "true"}, {"number": "21", "ReferenceId": "28202508", "FullCitation": "Lu Y, et al. Cancer Res. (2017) pmid: 28202508", "Include": "true"}, {"number": "22", "ReferenceId": "28148839", "FullCitation": "Sulkowski PL, et al. Sci Transl Med (2017) pmid: 28148839", "Include": "true"}, {"number": "23", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "24", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "25", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "26", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "27", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "28", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "29", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "30", "ReferenceId": "12175538", "FullCitation": "Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538", "Include": "true"}, {"number": "31", "ReferenceId": "12402306", "FullCitation": "Liu D, et al. Int. J. Cancer (2002) pmid: 12402306", "Include": "true"}, {"number": "32", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "33", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "34", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "35", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "36", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "37", "ReferenceId": "11780067", "FullCitation": "Lemon B, et al. Nature () pmid: 11780067", "Include": "true"}, {"number": "38", "ReferenceId": "21248752", "FullCitation": "Varela I, et al. Nature (2011) pmid: 21248752", "Include": "true"}, {"number": "39", "ReferenceId": "24185509", "FullCitation": "Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509", "Include": "true"}, {"number": "40", "ReferenceId": "18339845", "FullCitation": "Xia W, et al. Cancer Res. (2008) pmid: 18339845", "Include": "true"}, {"number": "41", "ReferenceId": "28921948", "FullCitation": "Hopson S, et al. ACS Chem. Biol. (2017) pmid: 28921948", "Include": "true"}, {"number": "42", "ReferenceId": "28053089", "FullCitation": "Porter EG, et al. J. Biol. Chem. (2017) pmid: 28053089", "Include": "true"}, {"number": "43", "ReferenceId": "26117423", "FullCitation": "Niimi A, et al. Mutat. Res. (2015) pmid: 26117423", "Include": "true"}, {"number": "44", "ReferenceId": "24613357", "FullCitation": "Brownlee PM, et al. Cell Rep (2014) pmid: 24613357", "Include": "true"}, {"number": "45", "ReferenceId": "25066234", "FullCitation": "Kakarougkas A, et al. Mol. Cell (2014) pmid: 25066234", "Include": "true"}, {"number": "46", "ReferenceId": "28082722", "FullCitation": "Gao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28082722", "Include": "true"}, {"number": "47", "ReferenceId": "25636086", "FullCitation": "Fujimoto A, et al. Nat Commun (2015) pmid: 25636086", "Include": "true"}, {"number": "48", "ReferenceId": "25536104", "FullCitation": "Churi CR, et al. PLoS ONE (2014) pmid: 25536104", "Include": "true"}, {"number": "49", "ReferenceId": "24867389", "FullCitation": "Simbolo M, et al. Oncotarget (2014) pmid: 24867389", "Include": "true"}, {"number": "50", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "51", "ReferenceId": "28988769", "FullCitation": "Robertson AG, et al. Cell (2017) pmid: 28988769", "Include": "true"}, {"number": "52", "ReferenceId": "28583311", "FullCitation": "Pietzak EJ, et al. Eur. Urol. (2017) pmid: 28583311", "Include": "true"}, {"number": "53", "ReferenceId": "32405805", "FullCitation": "Williams EA, et al. Acta Neuropathol. (2020) pmid: 32405805", "Include": "true"}, {"number": "54", "ReferenceId": "24974848", "FullCitation": "Petrini I, et al. Nat. Genet. (2014) pmid: 24974848", "Include": "true"}, {"number": "55", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "56", "ReferenceId": "24053427", "FullCitation": "da Costa WH, et al. BJU Int. (2014) pmid: 24053427", "Include": "true"}, {"number": "57", "ReferenceId": "22949125", "FullCitation": "Paw\u0142owski R, et al. Int. J. Cancer (2013) pmid: 22949125", "Include": "true"}, {"number": "58", "ReferenceId": "23036577", "FullCitation": "Hakimi AA, et al. Eur. Urol. (2013) pmid: 23036577", "Include": "true"}, {"number": "59", "ReferenceId": "23229642", "FullCitation": "Numata M, et al. Int. J. Oncol. (2013) pmid: 23229642", "Include": "true"}, {"number": "60", "ReferenceId": "23620406", "FullCitation": "Hakimi AA, et al. Clin. Cancer Res. (2013) pmid: 23620406", "Include": "true"}, {"number": "61", "ReferenceId": "22683710", "FullCitation": "Pe\u00f1a_Llopis S, et al. Nat. Genet. (2012) pmid: 22683710", "Include": "true"}, {"number": "62", "ReferenceId": "23333114", "FullCitation": "Kapur P, et al. Lancet Oncol. (2013) pmid: 23333114", "Include": "true"}, {"number": "63", "ReferenceId": "31486842", "FullCitation": "Braun DA, et al. JAMA Oncol (2019) pmid: 31486842", "Include": "true"}, {"number": "64", "ReferenceId": "32472114", "FullCitation": "Braun DA, et al. Nat Med (2020) pmid: 32472114", "Include": "true"}, {"number": "65", "ReferenceId": "29301960", "FullCitation": "Miao D, et al. Science (2018) pmid: 29301960", "Include": "true"}, {"number": "66", "ReferenceId": "32321774", "FullCitation": "Abou Alaiwi S, et al. Cancer Immunol Res (2020) pmid: 32321774", "Include": "true"}, {"number": "67", "ReferenceId": "32820162", "FullCitation": "Hakimi AA, et al. Nat Commun (2020) pmid: 32820162", "Include": "true"}, {"number": "68", "ReferenceId": "30150660", "FullCitation": "Miao D, et al. Nat. Genet. (2018) pmid: 30150660", "Include": "true"}, {"number": "69", "ReferenceId": "33850862", "FullCitation": "Yang Q, et al. Ann Transl Med (2021) pmid: 33850862", "Include": "true"}, {"number": "70", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "71", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "72", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "73", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "74", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "75", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "76", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "77", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "78", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "79", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "80", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "81", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "82", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "83", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "84", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "85", "ReferenceId": "26258846", "FullCitation": "Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846", "Include": "true"}, {"number": "86", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "87", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "88", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "89", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "90", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "91", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "92", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "93", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "94", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "95", "ReferenceId": "32416072", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32416072", "Include": "true"}, {"number": "96", "ReferenceId": "34554208", "FullCitation": "Zhu AX, et al. JAMA Oncol (2021) pmid: 34554208", "Include": "true"}, {"number": "97", "ReferenceId": "31300360", "FullCitation": "Lowery MA, et al. Lancet Gastroenterol Hepatol (2019) pmid: 31300360", "Include": "true"}, {"number": "98", "ReferenceId": "29860938", "FullCitation": "DiNardo CD, et al. N. Engl. J. Med. (2018) pmid: 29860938", "Include": "true"}, {"number": "99", "ReferenceId": "32530764", "FullCitation": "Mellinghoff IK, et al. J. Clin. Oncol. (2020) pmid: 32530764", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_12_29 16:26:17", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "769x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "3 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "LIVER", "disease_ontology": "Liver cholangiocarcinoma", "flowcell_analysis": "2000019381", "gender": "male", "pathology_diagnosis": "Cholangiocarcinoma, C22.1", "percent_tumor_nuclei": "30", "pipeline_version": "v3.9.0", "purity_assessment": "20.0", "specimen": "ORD_1256018_01*US1216136.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1256018_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Liver", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "772.24", "name": "SQ_US1216136.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.3447", "cds_effect": "658C>T", "depth": "644", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "34.47", "position": "chr1:156838380", "protein_effect": "R220W", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.2162", "cds_effect": "2800delT", "depth": "555", "equivocal": "false", "functional_effect": "frameshift", "gene": "PBRM1", "percent_reads": "21.62", "position": "chr3:52623250", "protein_effect": "S934fs*74", "status": "likely", "strand": "_", "transcript": "NM_018313", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.5659", "cds_effect": "1189C>A", "depth": "963", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "56.59", "position": "chr1:156844186", "protein_effect": "P397T", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.213", "cds_effect": "5429A>T", "depth": "432", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "21.3", "position": "chr12:133215834", "protein_effect": "H1810L", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.1659", "cds_effect": "394C>T", "depth": "693", "equivocal": "false", "functional_effect": "missense", "gene": "IDH1", "percent_reads": "16.59", "position": "chr2:209113113", "protein_effect": "R132C", "status": "known", "strand": "_", "transcript": "NM_005896", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.1726", "cds_effect": "772A>G", "depth": "1089", "equivocal": "false", "functional_effect": "missense", "gene": "BARD1", "percent_reads": "17.26", "position": "chr2:215645826", "protein_effect": "I258V", "status": "unknown", "strand": "_", "transcript": "NM_000465", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.4934", "cds_effect": "3934G>A", "depth": "531", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "49.34", "position": "chr13:110434467", "protein_effect": "G1312S", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.4032", "cds_effect": "3071A>T", "depth": "677", "equivocal": "false", "functional_effect": "missense", "gene": "TEK", "percent_reads": "40.32", "position": "chr9:27218783", "protein_effect": "Y1024F", "status": "unknown", "strand": "+", "transcript": "NM_000459", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.6521", "cds_effect": "128A>G", "depth": "802", "equivocal": "false", "functional_effect": "missense", "gene": "MYCL1", "percent_reads": "65.21", "position": "chr1:40367069", "protein_effect": "Y43C", "status": "unknown", "strand": "_", "transcript": "NM_005376", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"allele_fraction": "0.3452", "cds_effect": "217C>G", "depth": "730", "equivocal": "false", "functional_effect": "missense", "gene": "CDKN2B", "percent_reads": "34.52", "position": "chr9:22008736", "protein_effect": "R73G", "status": "unknown", "strand": "_", "transcript": "NM_078487", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "8", "equivocal": "true", "gene": "DDR2", "number_of_exons": "16 of 16", "position": "chr1:162688829_162750036", "ratio": "1.53", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"copy_number": "10", "equivocal": "false", "gene": "HSD3B1", "number_of_exons": "3 of 3", "position": "chr1:120050099_120057268", "ratio": "1.71", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}, {"copy_number": "10", "equivocal": "false", "gene": "NOTCH2", "number_of_exons": "34 of 34", "position": "chr1:120457928_120612048", "ratio": "1.71", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1216136.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.52", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}